Cure My Disease
Don't miss your cure!
Clinical trials sponsored by Stemline Therapeutics, Inc., explained in plain language.
This study tests a drug called elacestrant in 61 people with a common type of advanced breast cancer (ER+/HER2-). Participants have not received a specific class of drugs (CDK4/6 inhibitors) before. The goal is to see if elacestrant can slow or stop cancer growth over 6 months.
Phase: PHASE2 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated May 08, 2026 12:04 UTC